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ABSTRACT 
Global hypomethylation and regional hypermethylation are well-known epigenetic features 
of cancer, however, in chronic lymphocytic leukemia (CLL), studies on genome-wide 
epigenetic modifications are limited. Here we analyzed the global methylation profiles in 
CLL, by applying high-resolution methylation micro-arrays (27,578 CpG sites) to 23 CLL 
samples, belonging to the immunoglobulin heavy-chain variable (IGHV) mutated 
(favorable) and IGHV unmutated/IGHV3-21 (poor-prognostic) subsets. Overall, results 
demonstrated significant differences in methylation patterns between these subgroups. 
Specifically, in IGHV unmutated CLL, we identified methylation of 7 known or candidate 
tumor suppressor genes (e.g. VHL, ABI3 and IGSF4) as well as 8 unmethylated genes 
involved in cell proliferation and tumor progression (e.g. ADORA3 and PRF1 enhancing 
the NF-κB and MAPKinase pathways, respectively). In contrast, these latter genes were 
silenced by methylation in IGHV mutated patients. The array data was validated for 
selected genes using methylation-specific PCR, quantitative RT-PCR and bi-sulfite 
sequencing. Finally, the significance of DNA methylation in regulating gene promoters 
was shown by re-inducing 4 methylated tumor suppressor genes (e.g. VHL and ABI3) in 
IGHV unmutated samples using the methyl-inhibitor 5-aza-2’-deoxycytidine. Taken 
together, our data for the first time reveal differences in global methylation profiles 
between prognostic subsets of CLL, which may unfold epigenetic silencing mechanisms 
involved in CLL pathogenesis. 
 
Key words:  DNA methylation, micro-array, chronic lymphocytic leukemia, IGHV 
mutation status, IGHV3-21 usage. 
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INTRODUCTION 
Chronic lymphocytic leukemia (CLL) is characterized by clonal proliferation and 
accumulation of long-lived neoplastic B-cells, which arise due to altered control of 
apoptosis as well as proliferation. No common disease causing mutation has yet been 
identified in CLL, although certain recurrent genomic aberrations (i.e. 11q-, +12, 13q-, 
17p-) provide important prognostic information.1 Besides these aberrations, the mutation 
status of the immunoglobulin heavy-chain variable (IGHV) genes segregates patients into 
two main prognostic subgroups, where patients with unmutated IGHV genes show inferior 
outcome compared to those with mutated IGHV genes.2,3 In addition, CLL patients 
utilizing the IGHV3-21 gene display poor outcome independent of mutation status.4 
 Aberrant DNA methylation has been shown to play a strong role in tumorogenesis, 
where genome-wide hypomethylation and regional hypermethylation of tumor suppressor 
gene promoters are characteristic hallmarks of many cancers.5 In CLL, the epigenetic 
mechanism of gene regulation has thus far received limited attention. That 
notwithstanding, a strong correlation between promoter methylation and transcriptional 
silencing was shown for certain individual gene promoters in CLL, for example, DAPK1 
TWIST2, ZAP70 and HoxA4.6-9 The methylation status of several of these genes has also 
been reported to correlate with IGHV mutational status. To date, only one study has been 
performed using genome-wide methylation analysis in CLL using the ‘Restriction 
Landmark Genomic Scanning’ technique. They observed that 2–8% of CpG islands were 
aberrantly methylated compared to normal controls and that methylation events showed a 
non-random distribution.10 However, this technique spans only 3000 CpG islands and does 
not give a full coverage of the genome. 
 The main aim of this present investigation was to study and compare the genome-wide 
methylation profiles of different CLL prognostic subgroups to identify differentially 
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methylated genes that can play a role in CLL pathogenesis. Recent studies have revealed 
that DNA hypermethylation in cancer is not always restricted to discrete CpG islands or 
single genes but can affect multiple adjacent CpG rich regions resulting in gene silencing 
across large genomic distances.11 Unlike promoter CpG island methylation arrays that 
cover sites near the promoter region, we here applied an Illumina Infinium 
HumanMethylation27 array (27,578 methylated sites, covering 14,495 genes) to 23 CLL 
patient samples belonging to the IGHV mutated, IGHV unmutated and IGHV3-21 CLL 
subgroups. We identified distinct methylation profiles between different subgroups and the 
array data was validated for selected genes using methylation-specific PCR (MSP-PCR), 
real-time quantitative PCR (RQ-PCR) and bi-sulfite sequencing. Finally, methylated genes 
were also re-expressed in CLL patient samples using methyl inhibitors to ascertain the role 
of DNA methylation in regulating gene expression.  
 
MATERIALS AND METHODS 
Patient samples and Clinical data 
In this study, 23 tumor samples from patients with CLL (6 IGHV mutated, 7 IGHV 
unmutated and 10 IGHV3-21) were collected from the Biobank at the Department of 
Pathology, Uppsala University Hospital, Sweden. All samples were diagnosed according to 
recently revised criteria,12 showing typical CLL immunophenotype and ≥70% tumor cells. 
Clinical and molecular characteristics including IGHV mutation status and genomic 
aberrations are summarized in Table 1. Two normal healthy control samples (1 sample 
with peripheral blood mononuclear cells (PBMC) and 1 sample with CD19 sorted B-cells) 
and 1 negative control (whole-genome amplified DNA) were included for analysis. 
Additionally, 2 CLL EBV transformed cell lines (I83 derived from a mutated CLL patient 
and HG3 derived from an unmutated CLL patient) were included for analysis. Finally, 10 
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additional CLL samples (5 IGHV mutated and 5 IGHV unmutated) were included in the 
validation experiments using MSP-PCR and another 50 CLL samples (27 IGHV mutated 
and 23 IGHV unmutated) were included in RQ-PCR analysis. None of these 60 latter 
samples were included in methylation array analysis. Informed consent was obtained 
according to the Declaration of Helsinki and the study was approved by the local ethical 
review committee. 
 
Methylation array analysis 
We applied the genome-wide Illumina Infinium HumanMethylation27 BeadChip array 
(Illumina, San Diego, USA) which allows interrogation of 27,578 CpG dinucleotides, 
covering 14,495 genes. First, bi-sulfite conversion of genomic DNA was performed using 
the EZ DNA Methylation Kit (Zymo Research, Orange, CA, USA) according to the 
manufacturer’s protocol. Briefly, 1 µg of DNA was sodium bisulfite treated, denatured at 
95°C for 30 seconds, and bisulfite converted at 50°C for 12 hours. Following conversion, 
samples were desulphonated and eluted using column preparation. Approximately 100-125 
ng of bi-sulfite converted DNA was processed according to the Illumina Infinium 
Methylation Assay protocol. This assay is based on the conversion of unmethylated C-
nucleotides into U (T) -nucleotides by the bisulfite treatment. The DNA was whole-
genome amplified, enzymatically fragmented, precipitated, resuspended and hybridized 
over night at 48oC to locus specific oligonucleotide primers on the BeadArray. Following 
hybridization, the C or T nucleotides were detected by single base primer extension. The 
fluorescence signals corresponding to the C or T nucleotides were measured from the 
BeadArrays using an Illumina BeadStation GX scanner. The fluorescence data was then 
analyzed using the BeadStudio software (Illumina, San Diego, USA), which assigns a 
quantitative measure of the methylation levels (Beta-value or methylation index (MI) 
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value) for each CpG site, that corresponds to the ratio between the fluorescence signal 
from the methylated allele (C) and the sum of the fluorescent signals of the methylated (C) 
and unmethylated (T) alleles. The methylation status for each detected CpG site ranged 
between 0.1 (completely unmethylated) to 1 (completely methylated). MI cut-offs of ≥ 0.7 
and ≤ 0.4 (average of all MI values in each group) were considered methylated and 
unmethylated, respectively.  
    Further bioinformatic analysis of the methylation data was carried out in the freely 
available statistical computing language R (http://www.r-project.org). In order to search 
for the differentially methylated genes between the different prognostic subgroups (i.e. 
IGHV mutated/unmutated and IGHV3-21 CLL patients) the data was arcsin transformed 
and an empirical Bayes moderated t-test was then applied using the ‘limma’ package.  The 
p-values were adjusted using the method of Benjamini and Hochberg13 and a level of 
p<0.05 was used as a cutoff. To identify differentially methylated genes of largest 
difference between subgroups an additional filter incorporating the average geometric 
difference was applied to ensure only genes with large absolute differences remained. 
Consequently, an average difference in MI of 0.45 between the IGHV mutated and IGHV 
unmutated subgroups, 0.35 between the IGHV3-21 and IGHV mutated subgroups and 0.35 
between IGHV3-21 and IGHV unmutated subgroups was applied. 
  
Methylation-specific PCR analysis 
To verify the findings from the methylation arrays, we selected 4 genes for MSP-PCR. 
Methylated specific primers (MSP) were designed according to MSP primer selection 
criteria as outlined by Li and Dahiya.14 Specifically, sequences covering approximately 
250bp flanking the identified CpG sites on either side were used for primer design in the 
Methprimer software (Bisearch, San Francisco, USA). The unmethylated-specific primers 
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(USP) were designed around 50bp upstream and downstream of the methylation specific 
primers, as to cover the same CpG sites as those contained by the MSP region. Both MSP 
and USP primers are listed in Supplemental Table 1. The PCR reactions contained 1.5mM 
MgCl2, 200µM dNTP mix (Invitrogen, Carlsbad, CA, USA), 0.2µM primers (Sigma 
Aldrich, St. Louis, MO), 1x PCR AmpliTaq gold buffer, 1.25U AmpliTaq Gold (Applied 
Biosystems, Carlsbad, CA, USA), 5% DMSO (Merck, NJ, USA) and 50ng of bisulfite-
treated DNA. The PCR reaction was performed as follows: denaturation at 95 °C for 
10 minutes; 35 cycles of 94 °C for 45 seconds, 58°C for 45 seconds, 72 °C for 45 seconds 
and a final extension step of 72°C for 5 minutes. The PCR products were visualized on 2% 
agarose gels containing ethidium bromide. 
 
Real-time quantitative RT-PCR analysis 
To further analyze if methylation status influences the gene expression of specific genes, 
we selected 4 genes for RQ-PCR. Total RNA was extracted using RNA extraction Kit 
(Qiagen, Dusseldorf, Germany) according to the manufacturer’s protocol. Reverse 
transcription reaction was performed using MMLV-RT kit (Invitrogen, Carlsbad, CA) and 
random hexamers (Fermentas, Burlington, Canada) according to the manufacturer’s 
protocol. RT-PCR primers were designed using the Primer3 software (Broad institute, 
Boston, USA). All primer sequences are listed in Supplemental Table 1. Quantitative RT-
PCR analysis was performed using 2X SYBR green master mix according to 
manufacturer’s protocol (Fermentas, Burlington, Canada). Expression was analyzed using 
the Stratagene Mx 3005p (Stratagene, La Jolla, CA, USA) detection system and calculated 
with the Max Pro QPCR software (Stratagene) using beta-actin as a reference gene and the 
∆∆ Ct method. The statistical significance of differences in expression was calculated by a 
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t-test and represented in box plot graphs using the Statistica 8.0 software (Stat Soft, Tulsa, 
OK). 
 
Bi-sulfite sequencing 
To confirm the methylation status of individual genes, we selected 2 genes for bi-sulfite 
sequencing. Bi-sulfite sequencing primers (BSP) were designed according to BSP primer 
selection criteria as outlined by Li and Dahiya14 (Supplemental Table 1). PCR was 
performed using 1.5mM MgCl2, 200µM dNTP mix, 0.2µM primers (Sigma Aldrich, St. 
Louis, MO), 1x PCR Taq buffer, 1U Platinum Taq (Invitrogen, Carlsbad, CA, USA), and 
~50 ng of bi-sulfite-treated DNA. Touchdown PCR cycling conditions included 5 cycles at 
95 °C for 30 seconds, 55°C for 45 seconds and 72°C for 1 minute, followed by 5 cycles at 
95 °C for 30 seconds, 53°C for 45 seconds and 72°C for 1 minute, and a further 30 cycles 
at 94 °C for 30 seconds, 50°C for 45 seconds and 72 °C for 45 seconds, followed by a final 
extension step of 72°C for 5 minutes. The PCR product was cloned using the Invitrogen 
TOPO TA cloning kit-2.1 TOPO vector (Invitrogen, Carlsbad, CA, USA), and 10-12 
clones per sample were selected for verification of the correct sized insert via PCR using 
vector specific M13 forward and reverse primers (provided by the cloning kit). Verified 
PCR products were treated using 0.5 U Exo I and 1.0 U SAP (Fermentas, Burlington, 
Canada) at 37oC for 45 minutes and 80oC for 15 minutes and sequenced with vector 
specific primers using the BigDye Terminator Cycle Sequencing Reaction Kit (Perkin-
Elmer, Foster City, CA). All sequence reactions were analyzed using an automated DNA 
sequencer (ABI 377, Applied Biosystems, Foster City, CA). Sequences were aligned and 
analyzed using the bisulfite sequencing web-based tool BiQ Analyzer software (Max-
Planck Institut fur informatik, Saarbrucken, Germany) and the degree of methylation 
represented as a lolli-pop grid. 
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5-aza-2’-deoxycytidine (DAC) and Trichostatin A (TSA) treatment  
Frozen primary CLL cell samples and the CLL cell line HG3 were cultured in RPMI-1640 
media supplemented with 10% FBS (Sigma Aldrich, St. Louis, MO) 4mM glutamine and 
1X penicillin/streptomycin (Invitrogen, Carlsbad, CA, USA) until confluent. Cells were 
then subdivided to contain ~ 1 million cells/ml/well 12 hours before treatment, to allow the 
cells to adjust to conditions. Cells were subsequently cultured over 3 days in supplemented 
RPMI media treated with one of the following treatments: 1) medium containing 5-aza-2’-
deoxycytidine (DAC) (5µM/L, Sigma Aldrich, St. Louis, MO) for 72 hours whereby 
medium was changed every 24 hours, 2) medium containing Trichostatin A (TSA) 
(500nM/lit, Sigma Aldrich, St. Louis, MO) for the last 24 hours, and 3) medium containing 
DAC for 48 hrs followed by addition of TSA for 24 hrs. Control cells were cultured in 
similar way with no drugs added. 
 
RESULTS 
Distribution of samples based on overall methylation index 
This study investigated a total of 27 samples, encompassing 6 IGHV mutated, 7 IGHV 
unmutated, and 10 IGHV3-21 CLL patient samples, as well as 2 healthy control samples (1 
obtained from PBMC and 1 from sorted B-cells), 2 EBV transformed CLL cell lines and 1 
negative control (whole-genome amplified DNA). Figure 1 graphically represents the MI 
values obtained from all samples. As expected the negative control sample showed lowest 
MI, and the healthy control samples displayed the highest values. All CLL patient samples 
fell in the range between these controls, whereas the two CLL cell lines displayed lower 
MIs when compared to the CLL samples. Hence, healthy controls had a higher degree of 
genome-wide methylation, whereas the CLL cell lines showed less methylation compared 
to the CLL patient samples.  
10 
 
Methylation profiling of different prognostic subgroups of CLL 
Genome-wide methylation profiles were compared between samples from three different 
CLL subgroups, i.e. IGHV mutated, IGHV unmutated and IGHV3-21 CLL. Additionally, 
healthy controls were included for comparison. Since the CLL cell lines showed 
completely different methylation profiles as compared to CLL patient samples, these were 
not included in the comparisons. Using highly stringent selection criteria (as detailed in 
Materials and Methods), a total of 64 genes were identified as significantly differentially 
methylated between IGHV mutated and unmutated CLL (Figure 2A). Similarly, 60 and 31 
genes were identified in the comparison between IGHV unmutated versus IGHV3-21 CLL 
and IGHV mutated versus IGHV3-21 CLL, respectively (Figure 2B-C). Based on the 
functionality of all these identified differentially methylated genes, they could be grouped 
into various categories, such as apoptotic related genes (anti-apoptotic or pro-apoptotic), 
known or candidate tumor suppressor genes, genes involved in high proliferative activity, 
genes enhancing tumorogenesis, drug resistance genes and genes associated with 
prognosis, as described in Table 2. Importantly, we identified known/candidate tumor 
suppressor genes that were preferentially methylated in the IGHV unmutated (7 genes, e.g. 
VHL, ABI3), IGHV3-21(1 gene, SLC22A18) and IGHV mutated (2 genes, PPP1R3A and 
WISP3) subgroups. We also identified 10 unmethylated and hence potentially expressed 
genes shown to be involved in activation of proliferative pathways such as the NFκB 
pathway (e.g. ADORA3 and CARD15), and the MAP/ERK kinase pathway (e.g. PRF1 and 
FABP7) in the IGHV unmutated and IGHV3-21 subgroups. Of the identified genes, most 
have previously not been associated with CLL, however many were known to be involved 
in the tumorogenesis of several other cancers and leukemia.  
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Confirmation of array data using methylation-specific PCR and RQ-PCR 
To confirm the array data, we selected 4 genes for MSP-PCR, i.e. PRF1 and ADORA3 
(methylated in IGHV mutated CLL samples), BCL10 and IGSF4 (methylated in IGHV 
unmutated CLL samples). PRF1 and ADORA3 are mainly involved in cell proliferation by 
constitutive activation of the MAPK and NFκB pathways, respectively,15,16 whereas 
BCL10 is an anti-apoptotic gene17 and IGSF4 is a candidate tumor suppressor gene.18 
Figure 3A illustrates the results for 3 IGHV mutated and 4 unmutated CLL samples, 
verifying that PRF1 and ADORA3 were mostly methylated in mutated samples, whereas 
mostly BCL10 and IGSF4 were methylated in unmutated samples. Additionally, we 
selected 10 additional IGHV mutated and unmutated CLL samples (not included in the 
array study), and analyzed the methylation status for ADORA3 and BCL10, which further 
confirmed the divergent methylation status between the mutated/unmutated CLL 
subgroups (Figure 3B). 
 Following conformation of the methylation status of the selected genes, we correlated 
this data with mRNA expression levels of the respective genes as well as 3 additional 
genes (i.e. VHL, ABI3 and NGFR) using RQ-PCR. Figure 4 demonstrates RQ-PCR results 
for 4 of the genes (VHL, ABI3, ADORA3 and BCL-10) in a CLL cohort of 50 samples, 
confirming that the mRNA expression levels correlated strongly with the methylation 
status. Of the 4 genes analyzed, 3 genes (VHL, ABI3 and BCL-10) showed a significant 
difference between the IGHV mutated and unmutated subgroups. Furthermore, RT-PCR 
results for the PRF1 and NGFR genes (Supplemental Figure 1) were analyzed on the same 
4 IGHV mutated and unmutated samples included in the MSP-PCR analyses, further 
verifying the MSP-PCR data.  
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Bi-sulfite sequencing of methylated tumor suppressor genes 
Two candidate tumor suppressor genes (VHL and ABI3) that displayed significant 
differences in gene expression levels between IGHV mutated and unmutated CLL samples 
were selected for bi-sulfite sequencing and subcloning to confirm the degree of 
methylation using 2 IGHV mutated and 2 IGHV unmutated samples. The bi-sulfite 
sequencing region covered the CpG sites which were included in the array and showed a 
significant difference in the MI values between IGHV mutated and IGHV unmutated 
samples. Both genes exhibited a high degree of hypermethylation in the IGHV unmutated 
samples compared to the IGHV mutated samples (Figure 5). 
 
Re-expression of methylated genes using a methyl inhibitor 
To investigate the role of DNA methylation in transcriptional regulation of gene 
promoters, we examined the effects of DNA methyl transferase inhibitor 5-aza-2’-
deoxycytidine (DAC) and/or histone deacetylase inhibitor trichostatin A (TSA) treatment 
on gene expression in 3 IGHV unmutated and 3 IGHV mutated CLL samples. Four genes 
found to be mainly hypermethylated in unmutated samples (IGSF4, VHL, ABI3 and NGFR) 
were selected for re-expression analysis. An increase in the activation of the IGSF4, ABI3 
and VHL genes was observed in response to DAC or TSA treatment, especially when 
applied in combination, in several of the IGHV unmutated CLL samples as compared to 
the corresponding untreated samples (Figure 6). Reactivation of the NGFR gene is shown 
in Supplemental Figure 2. Similar data was obtained for all the above mentioned genes 
using the CLL EBV transformed cell line HG3 (data not shown). 
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DISCUSSION 
In hematological malignancies, genes involved in important cellular pathways have been 
described to be affected by CpG island methylation in association with transcriptional 
silencing.19 The role of aberrant DNA methylation and individual DNA promoter 
methylation has been investigated in CLL (e.g. ZAP-70, TWIST 2)6,7, although there have 
been few comprehensive studies dedicated to uncover the methylation status on a global 
level. Using a genome-wide methylation array, we here for the first time identified distinct 
methylation profiles in prognostic subsets of CLL. 
 In tumor cells, a disrupted methylation pattern is often observed featuring global 
hypomethylation and region-specific hypermethylation of certain gene promoters, 
compared to their normal cellular counterparts. In the present study the overall degree of 
methylation, indicated as MI values, of all CLL primary samples demonstrated lower 
methylation levels compared to normal healthy controls (Figure 1), which is in line with 
previous findings.20 We also noticed that the EBV-transformed CLL cell lines displayed 
very different methylation patterns compared to CLL primary samples with lower MI 
values. This is perhaps not unexpected considering their higher proliferative capacity.   
 To identify differentially methylated genes between CLL subgroups we applied a 
stringent bioinformatic approach which revealed significantly different methylation 
profiles between IGHV unmutated and mutated CLL as well as between IGHV 
mutated/unmutated and IGHV3-21 CLL (Figure 2). Many of the identified genes were 
found to be involved in important cellular pathways, where dysregulation of these genes 
could significantly contribute to leukemogenesis. For instance, we identified known or 
candidate tumor suppressor genes that were preferentially methylated in the poor-
prognostic IGHV unmutated (7 genes) and IGHV3-21 (1 gene) subgroups (Table 2). 
Although many of these genes have been implicated in several other cancers (Table 2), 
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their role in CLL has not been investigated. Some of the known or candidate tumor 
suppressor genes that were specifically methylated in IGHV unmutated CLL were: ABI3, 
implicated in lung metastasis21, VHL, mutated in sporadic renal cell carcinoma as well as in 
the hereditary syndrome von Hippel-Lindau22 and IGSF4, methylated in neuroblastoma18. 
Furthermore, we performed validation experiments to verify the methylation data from the 
arrays. For instance, the high degree of methylation and the corresponding decreased gene 
expression of 2 genes, VHL and ABI3, were confirmed by both bi-sulfite sequencing and 
RQ-PCR in IGHV unmutated CLL (Figure 4 and 5). Taken together, several tumor 
suppressor genes were found methylated particularly in poor-prognostic, unmutated CLL, 
while they remained unmethylated and hence expressed in IGHV mutated CLL.  
 Previous studies implicate that certain cellular pathways, such as NFκB, PI3K/Akt and 
MEK/ERK, are dysregulated in CLL B-cells leading to activation of anti-apoptotic 
pathways. Our data strengthens this idea and further indicates that certain genes involved 
in such ‘proliferative’ pathways may be controlled by DNA methylation in CLL. In 
particular, we identified expression of genes that enhance constant cell proliferation and 
invasion in the IGHV unmutated CLL subgroup (Table 2). Some of the genes included 
were ADORA3 and PRF1 genes, that activate the NFκB and MAPKinase pathways, 
respectively, and which were expressed in the poor-prognostic CLL subsets compared to 
IGHV mutated CLL.16,23 Also, genes involved in repressing the NFκB pathway (LCOD1 
gene)28 and MAPKinase (ZNF540 gene)29 pathways were generally methylated in both 
IGHV unmutated and IGHV3-21 samples in contrast to IGHV mutated CLL. The 
methylation status and gene expression were confirmed for two such genes, e.g. ADORA3 
and PRF1 using both MS-PCR and RQ-PCR in IGHV unmutated versus mutated CLL 
(Figure 3 and 4). Moreover, genes previously reported to be involved in facilitating 
tumorogenesis within other cancer types were noted to be preferentially unmethylated in 
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the IGHV unmutated (7 genes) and IGHV3-21 (4 genes) CLL subgroups in comparison to 
IGHV mutated CLL (Table 2). For example, IFNB1, shown to enhance B-cell 
proliferation,24 and IL17RC, involved in facilitating tumorogenesis in prostate cancer,25 
were unmethylated in IGHV unmutated samples.  Thus, the above data indicates that poor-
prognostic CLL subsets favor expression of genes aiding tumor proliferation. 
 In contrast to IGHV unmutated CLL, IGHV mutated CLL showed mainly deregulation 
of anti- and pro-apoptotic genes. In particular, BCL2, a known anti-apoptotic gene,26 
remained unmethylated in IGHV mutated CLL samples. On the other hand, pro-apoptotic 
genes such as BCL1017 and TP5313 shown to induce p53-mediated cell death,27 were 
methylated in IGHV mutated samples unlike IGHV unmutated CLL. As shown in Figure 
3, we could confirm both the differential methylation status and expression level of BCL10 
in mutated and unmutated CLL. 
 Interestingly, we also identified certain genes that have been related to prognosis, for 
instance, the ANGPT2 gene which has been shown to be expressed preferentially in IGHV 
unmutated CLL samples.28 Our array data indeed demonstrated that this gene was 
methylated in mutated CLL while being unmethylated in unmutated CLL. In addition, 
expression of the NGFR gene, which has been associated with favorable prognosis in 
ALL,29 was unmethylated in IGHV mutated CLL and showed increased expression on the 
RNA level within this subset (Supplemental Figure 1). However, further analysis of the 
ANGPT2 and NGFR genes in a larger CLL cohort is needed to assess their prognostic 
impact. ¨ 
 Apart from the ‘traditional’ genes, the HumanMethylation27 BeadChip array also 
contains 110 miRNA promoters. However, none of these miRNAs met the criteria set to 
define a significant difference in methylation between the studied subsets. Evidently, this 
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does not exclude that methylation changes may exist between CLL subsets considering that 
only a fraction of miRNA promoters were covered by the array.  
 Unlike genetic changes, epigenetic changes are reversible using de-methylating agents 
such as 5-aza-deoxycytidine (DAC). Consequently, the role of these agents as treatment 
options is currently under investigation in hematological malignancies including CLL.33,34  
In this study, we demonstrated that inhibition of DNA methylation using methyl- and 
HDAC inhibitors could induce expression of methylated tumor suppressor genes (e.g. 
IGSF4, ABI3 and VHL) in unmutated CLL primary samples. We generally did not observe 
high induction of gene expression with methyl inhibitor treatment, probably due to the fact 
that CLL primary cells do not proliferate at a high rate under in vitro conditions, although 
the effect of the drugs was pronounced when applied in combination. These data indeed 
strengthen the role of DNA methylation in regulating promoter expression and open up the 
possibility of targeted therapy, although this has to be studied further.  
 Gene expression micro-array studies have previously revealed different gene 
expression profiles between IGHV mutated and IGHV unmutated/IGHV3-21 CLL 
patients. 30-32  However, the vast majority of the identified genes in the present study could 
not be found in these gene expression studies.30-32 There could be several possible 
explanations for this, for example, incomplete overlap with genes included on the 
expression arrays, and different criteria applied for identifying genes differing between 
subsets. Gene expression can also be silenced by other mechanisms than methylation, for 
instance mutations or deletions, which will not be identified on methylation arrays. Also, 
we cannot exclude the possibility that differentially methylated genes may not always 
correlate with a significant difference in gene expression. Since this is one of the first 
studies using the whole-genome Illumina array, we decided to apply stringent criteria in 
order to reduce false positive genes. On the other hand, we may indeed have lost some 
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important genes, which would have come up using less stringent criteria. That 
notwithstanding, we believe that our confirmation experiments using different techniques 
such as MSP-PCR, RQ-PCR and bi-sulfite sequencing strengthen the validity of our data. 
 In conclusion, the observation that the distinct methylation profiles encompassed 
candidate genes involved in cellular pathways regulating proliferation and apoptosis in 
IGHV unmutated and mutated CLL underlines a critical role for epigenetic changes during 
leukemogenesis. Most identified tumor suppressor genes were specifically silenced in 
IGHV unmutated CLL, implicating the role of these genes in the pathogenesis of this 
subgroup. Specific inhibition of expression of unmethylated genes involved in facilitating 
tumorogenesis and re-expression of methylated candidate tumor suppressor genes within 
the poor-prognostic subgroups could represent a possible route for drug therapy. 
Hopefully, our results may help to further unravel the pathogenesis of CLL and identify 
possible novel biomarkers and targets for drug therapy in CLL. 
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Table 1. Clinical and molecular data for the CLL patients included. 
 
 
 
a IGHV gene analysis was performed using PCR amplification and nucleotide sequencing as previously described.35 
Cases with ≥98% identity to germline were classified as unmutated, whereas cases with <98% identity were 
considered mutated. IGHV3-21 cases were classified as stereotyped (#) or non-stereotyped according to Murray et 
al. 35 
b Months from diagnosis to last observation or death.(+) indicates that the patient is alive.  
c Denotes treatment status before sampling, (yes) indicates that the patient was treated before sampling, whereas 
(no) indicates that the patient remained untreated.  
d Known recurrent aberrations, i.e. del(13q), del(11q), del(17p) and trisomy 12, were determined using FISH 
analysis (1), SNP-array analysis (2) or quantitative PCR analysis (3). FISH analysis was performed using 
commercially available probes as decribed previously,36 whereas SNP array analysis was performed using high-
resolution Affymetrix 250K SNP-arrays from which data on known recurrent genomic aberrations were 
extracted.36 Quantitative PCR was performed by applying specifically designed primers for each locus (primers 
available on request) using the SYBR green master mix according to the manufacturer’s protocol (Fermentas, 
Burlington, Canada). Copy-number changes were normalized against a copy-number neutral internal control 
region and ratios relative to the DNA copy-number from a pooled control (Promega, Madison) were tallied for 
each locus. 
* A second mutated, in-frame IGHV gene rearrangement (92% identity) was also detected in this case. 
ND, not defined. 
CLL sample 
 
 
Percent 
identitya 
 
Age at 
diagnosis 
(years) 
Gender 
 
 
Survival 
(months)b 
 
Binet 
stage 
 
Treated 
before 
samplingc 
Genomic 
aberrationsd 
 
IGHV mutated 
      
M1 94.6 63 M 195+ A No del(13q)3 
M2 91.5 74 M 55 A No del(13q)1 
  M3* 93.2 72 M 129+ A ND None3 
M4 94.1 70 M 134+ A No del(13q)3 
M5 91.3 65 M 104+ A No del(13q)1 
M6 91.1 64 F 94+ A No None3 
IGHV unmutated       
UM1 100.0 49 M 99 A Yes del(11q)3 
UM2 100.0 44 M 84 B ND del(11q)3 
UM3 100.0 79 M 10 B No ND 
UM4 100.0 82 F 50 B No ND 
UM5 100.0 57 M 49 B No del(13q)1 
UM6 100.0 69 M 24 C No None3 
UM7 100.0 51 M 112+ A No None1 
IGHV3-21 
       
3-21-1 100.0 45 F 58 ND ND +122 
3-21-2 100.0 63 M 58 C No del(13q), del(11q)1 
3-21-3   96.50# 61 M 52 C No del(13q),del(11q)1 
3-21-4 96.9# 62 F 67 ND No del (13q)2 
3-21-5 100.0 65 F 52 ND Yes del(17p),+121 
3-21-6 98.7# 67 M ND ND ND del(13q),del(11q)1 
3-21-7   96.49# 63 M ND ND ND del(13q)3 
3-21-8 95.5# 60 M 72 B No None1 
3-21-9 96.8# 62 M 111 ND ND del(13q)2 
3-21-10 97.4# 76 M 82 A No del(13q), del(11q)2 
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 Table  2. Functional characterization of selected differentially methylated genes. 
 A. IGHV mutated and IGHV unmutated CLL 
Functionality of 
genes 
Gene 
names 
IGHV 
mutated 
IGHV 
unmutated 
Implicated role in cancer Accession 
number Ref 
 
      
Tumor  ABI3* Unmethylated Methylated Lost in cancer cell lines,  implicated in lung metastasis NM_016428.3 21
 
  suppressor genes SCGB2A1* Unmethylated Methylated Methylated in lung cancer NM_002407.1 37
 
  
VHL Unmethylated Methylated Mutated in sporadic cell renal carcinoma and von Hippel-Lindau syndrome NT_022517.17 22
 
  
PPP1R3A* Methylated Unmethylated Deregulated in colorectal cancer NM_002711.2 38
 
  
WISP3 Methylated Unmethylated Loss of expression  in inflammatory breast cancer NM_003880.2 39
 
 
     
 
Genes enhancing  ADORA3 Methylated Unmethylated Activation of the NFκB pathway NM_020683.5 15
 
  proliferation AIRE Methylated Unmethylated Regulated by the PKC pathway NM_000383.1 40
 
  
CARD15 Methylated Unmethylated Activation of the NFκB pathway NM_022162.1 41
 
  
FABP7 Methylated Unmethylated Regulated by the MAPK/ERK pathway NM_001446.3 42
 
  
LOC340061 Methylated Unmethylated Activation of the NFκB pathway NM_198282.1 23
 
  
PRF1 Methylated Unmethylated Enhancing the MAPKinase pathway NM_005041.3 16
 
  
UNC5CL Methylated Unmethylated Activation of the NFκB pathway NM_173561.1 43
 
 
     
 
Genes facilitating  ANGPT2 Methylated Unmethylated Preferentially expressed in unmutated CLL NM_001147.1 28
 
  tumorogenesis IFNB1 Methylated Unmethylated Shown to enhance B-cell proliferation NM_002176.2 24
 
  
URP2 Methylated Unmethylated Implicated in facilitating CLL tumorogenesis NM_031471.4 44
 
 
     
 
Anti-apoptotic  BCL2 Methylated Unmethylated Known anti-apoptotic gene, up-regulated in many cancers NT_025028.13 26
 
  genes PLD1 Unmethylated Methylated Stimulates cell cycle progression by repressing p53 regulation of p21  NM_002662.2 45
 
 
     
 
Pro-apoptotic  BCL10 Unmethylated Methylated Pro-apoptotic genes, involved in p53 mediated cell death NM_003921.2 17
 
  genes IL19 Methylated Unmethylated Regulating apoptosis by activation of the STAT3 pathway  NM_013371.2 46
 
 
     
 
Genes involved in 
prognosis 
NGFR Unmethylated Methylated Highly expressed in favorable prognostic ALL patients NM_002507.1 29
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 B. IGHV unmutated and IGHV3-21 CLL 
Functionality of 
genes 
Gene 
names 
IGHV 
unmutated IGHV3-21 
Implicated role in cancer Accession 
number Ref 
 
   
 
  
Tumor ABI3* Methylated Unmethylated Lost in cancer cell lines, implicated in lung metastasis  NM_016428.3 21
 
suppressor GPX3 Methylated Unmethylated Deleted or methylated in prostate cancer NM_002084.2 47
 
genes IGSF4* Methylated Unmethylated Down-regulated  by  methylation in  neuroblastoma  NM_014333.2 18
 
 
SERPIND5* Methylated Unmethylated Tumor suppressive properties in breast cancer  NM_002639.2 48
 
 
SLC22A18 Unmethylated Methylated Deregulated in several cancer forms NM_183233.1 49
 
 
 
    
 
Genes  repressing LDOC1 Unmethylated Methylated Implicated in repressing the NFκB pathway NM_012317.2 50
 
proliferation ZNF540 Methylated Unmethylated Involved in down-regulating the MAPKinase pathway  NM_152606.2 51
 
 
 
    
 
Genes  facilitating IL17RC Unmethylated Methylated Shown to facilitate tumorogenesis in prostate cancer  NM_032732.2 25
 
tumorogenesis ANGPT2 Unmethylated Methylated Expressed in IGHV unmutated CLL NM_001147.1 28 
 
FHL2 Methylated Unmethylated  NM_201556.1 
 
 
S100A14 Unmethylated Methylated  NM_020672.1 
 
 
 
    
 
Anti-apoptotic BCL2 Unmethylated Methylated Known anti-apoptotic gene,  up-regulated in many cancers NT_025028.13 26
 
genes PLD1 Methylated Unmethylated Stimulates cell cycle progression by repressing p53 regulation of p21  NM_002662.2 45
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* These genes represent candidate tumor suppressor genes. 
 C. IGHV mutated and IGHV3-21 CLL 
Functionality Gene 
names 
IGHV 
mutated IGHV3-21 
Implicated role in cancer Accession 
number Ref 
 
   
 
  
Genes enhancing LOC340061 Methylated Unmethylated Activation of the NFκB pathway NM_198282.1 23
 
proliferation PRF1 Methylated Unmethylated Enhancing the MAPKinase pathway NM_005041.3 16
 
 
RASGRP3 Methylated Unmethylated Regulated B-cell proliferation by facilitating B cell receptor-RAS signaling NM_170672.1 52
 
 
     
 
Genes  facilitating LMO2 Methylated Unmethylated Known proto-oncogene, expressed in human B-cell lymphomas NM_005574.2 53
 
tumorogenesis URP2 Methylated Unmethylated Implicated in facilitating CLL tumorogenesis NM_031471.4 44
 
 
NCRMS Methylated Unmethylated  XR_000219.2 
 
 
     
 
Pro-apoptotic TP53I3 Methylated Unmethylated Shown to induce p53 mediated cell death NM_004881.2 27
 
genes BCL10 Unmethylated Methylated Pro-apoptotic genes, involved in p53 mediated cell death NM_003921.2 17
 
 
     
 
Genes involved in  DNTT Methylated Unmethylated Associated with poor prognosis in acute myeloid leukemia NM_004088.3 54
 
prognosis 
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FIGURE LEGENDS 
Figure 1. Methylation indices (MI) for the 27 samples included in the present study.  
 
Figure 2: Supervised hierarchical clustering of methylated/unmethylated genes between CLL 
subgroups. Three different comparisons were made: (A) IGHV mutated (samples M1 to M6) 
vs. IGHV unmutated (samples UM1 to UM7), (B) IGHV unmutated vs. IGHV3-21 (samples 
3-21-1 to 3-21-10) and (C) IGHV mutated vs. IGHV3-21. Two normal healthy control 
samples and 1 negative control were included for comparison. A gradient color scale ranging 
between green (completely unmethylated) and red (completely methylated) is included.  
 
Figure 3. Validation experiments using MSP-PCR. Methylation-specific PCR was performed 
for the PRF1, ADORA3, BCL10 and IGSF4 genes, using bisulfite treated DNA from IGHV 
mutated samples (M1-3 to M8-12) and IGHV unmutated samples (UM1-4 and UM8-12). 
Figure 3A shows data for samples analyzed in the methylation array whereas Figure 3B 
includes results from additional CLL samples. Analysis of each gene in Figure 3A/B was 
performed during the same experiment and on the same gel, vertical line(s) have been inserted 
to indicate a repositioned gel lane. N: normal PBMC sample; M: methylation-specific 
primers; U: unmethylation-specific primers.  
 
Figure 4. Validation experiments using quantitative RT-PCR. Relative expression data 
presented as box plots for the following genes: VHL, AB13, ADORA3 and BCL10. 27 IGHV 
unmutated and 23 IGHV mutated CLL cases were investigated that had been not included in 
the methylation array analysis. p-values are indicated above each box plot. Boxes indicate the 
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interquartile range (25-75%) with the smaller inner square indicating the median. The 
whiskers show the minimum and maximum values, except for outliers (circles). 
 
Figure 5. Bi-sulfite sequencing of 2 tumor suppressor genes. (A) VHL and (B) AB13. Results 
from 2 IGHV mutated and 2 IGHV unmutated CLL samples are shown. Black lollipops; 
methylated CpG sites and white lollipops; unmethylated CpG sites.    Indicates a polymorphic 
site.   
 
Figure 6. RT-PCR analysis showing the re-expression of methylated tumor suppressor genes 
in unmutated CLL. Three different candidate tumor suppressor genes, (A) IGSF4, (B) AB13 
and (C) VHL were investigated in 3 IGHV unmutated CLL samples (UM1 to UM3, shown in 
different colors) with and without treatment using the methyl inhibitor 5-aza-2’-deoxycytidine 
(DAC), the histone deacetyl (HDAC) inhibitor, Trichostatin A (TSA) or in combination. Con, 
control. 
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